Most Attractive Stocks: Bank of America, Amylin Pharmaceuticals, Bristol Myers Squibb, Constellation Brands, US Airways Group, and Alpha Natural Resources
VANCOUVER, British Columbia, July 3, 2012 /PRNewswire-Asia/ -- Insiderslab.com has issued insider trading reports and Equity Research for the following companies: Bank of America (NYSE:BAC), Amylin Pharmaceuticals (NASDAQ:AMLN), Bristol Myers Squibb (NYSE:BMY), Constellation Brands (NYSE:STZ), US Airways Group (NYSE:LCC), and Alpha Natural Resources (NYSE:ANR).
(Read full report by clicking the link below, you may need to copy and paste the full link to your browser.)
Bank of America Corporation (NYSE:BAC): Recently, Bank of America Corporation (NYSE:BAC) employed over 30 small business bankers in the state of Washington for supplying guidance and counsel to local small business owners. This is a part of the company's plan of employing about 1,000 small business bankers in the state. By the end of Monday's trading, Bank of America shares slumped 1.59% to US$8.05. There were 152.25 million shares of Bank of America exchanging hands as compared to its average daily volume of 193.91 million shares. Are Bank of America insiders starting to take huge profits by selling shares or exercising stock options? According to academic studies, insiders traditionally make higher investment returns than ordinary investors. Want to find out how they do it?
Read Full Report: http://www.insiderslab.com/PR3/070312A/BAC/BankofAmerica.pdf
Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN): Abnormal trading volume of Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN) was found on July 2 reaching 98.43 million shares, 29.6 times heavier than usual day trading. Amylin Pharmaceuticals shares soared 8.88% to US$30.70 and made a new 52-week high of US$30.75. According to the report of Amylin Pharmaceuticals, Inc. announced on June 29, Bristol-Myers Squibb Company will acquire Amylin for US$31.00 per share in cash, or an aggregate purchase price of US$5.3 billion. Since Amylin Pharmaceuticals insiders such as CEOs, CFOs and Directors have better access to company non-public information, Insiderslab.com thinks that investors would be wise to pay close attention to their stock trading behaviors. Check this insider trade report for AMLN here.
Read Full Report: http://www.insiderslab.com/PR3/070312A/AMLN/Amylin.pdf
Bristol Myers Squibb Co. (NYSE:BMY): Insiderslab.com found eight Market Option Sale (Planned) made by company Director -- James M. Cornelius from June 5 through June 27, with shares ranging from US$33.69 to US$35.07 each. On June 29, Bristol Myers Squibb Co. (NYSE:BMY) announced that the company has decided to acquire Amylin Pharmaceuticals, Inc. for approximately US$5.3 billion. After the completion of Bristol-Myers Squibb's acquisition of Amylin, Bristol-Myers Squibb and AstraZeneca will form a partnership involving in the development and commercialization of Amylin's portfolio of products. Moreover, AstraZeneca will pay approximately US$3.4 billion to Amylin. The companies said that profits and losses arising from the collaboration will be shared equally. In addition, Bristol Myers Squibb is scheduled to release its financial results for second quarter 2012 on Wednesday, July 25, 2012. By market close, Bristol Myers Squibb shares climbed 0.28% to US$36.05 and made a new 52-week high of US$36.34. The stock traded 15.64 million shares, well above its daily average of 10.77 million shares. Investors may want to find out how Bristol Myers Squibb insiders are thinking about the future of the company. Check this insider trade report for BMY here.
Read Full Report: http://www.insiderslab.com/PR3/070312A/BMY/BristolMyersSquibb.pdf